Taiwan · Delayed Price · Currency is TWD Sage Therapeutics Statistics
Total Valuation
PharmaEssentia has a market cap or net worth of TWD 169.63 billion. The enterprise value is 148.58 billion.
| Market Cap | 169.63B |
| Enterprise Value | 148.58B |
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PharmaEssentia has 333.27 million shares outstanding. The number of shares has increased by 1.10% in one year.
| Current Share Class | 333.27M |
| Shares Outstanding | 333.27M |
| Shares Change (YoY) | +1.10% |
| Shares Change (QoQ) | -0.18% |
| Owned by Insiders (%) | 8.77% |
| Owned by Institutions (%) | 7.89% |
| Float | 262.18M |
Valuation Ratios
The trailing PE ratio is 43.63 and the forward PE ratio is 25.00.
| PE Ratio | 43.63 |
| Forward PE | 25.00 |
| PS Ratio | 14.96 |
| PB Ratio | 5.82 |
| P/TBV Ratio | 5.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 46.96, with an EV/FCF ratio of 50.09.
| EV / Earnings | 38.11 |
| EV / Sales | 13.10 |
| EV / EBITDA | 46.96 |
| EV / EBIT | 52.62 |
| EV / FCF | 50.09 |
Financial Position
The company has a current ratio of 9.07, with a Debt / Equity ratio of 0.03.
| Current Ratio | 9.07 |
| Quick Ratio | 8.48 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.31 |
| Debt / FCF | 0.33 |
| Interest Coverage | 125.64 |
Financial Efficiency
Return on equity (ROE) is 14.56% and return on invested capital (ROIC) is 6.34%.
| Return on Equity (ROE) | 14.56% |
| Return on Assets (ROA) | 5.86% |
| Return on Invested Capital (ROIC) | 6.34% |
| Return on Capital Employed (ROCE) | 9.39% |
| Revenue Per Employee | 86.55M |
| Profits Per Employee | 29.76M |
| Employee Count | 131 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 0.94 |
Taxes
In the past 12 months, PharmaEssentia has paid 221.86 million in taxes.
| Income Tax | 221.86M |
| Effective Tax Rate | 5.38% |
Stock Price Statistics
The stock price has decreased by -21.09% in the last 52 weeks. The beta is -0.08, so PharmaEssentia's price volatility has been lower than the market average.
| Beta (5Y) | -0.08 |
| 52-Week Price Change | -21.09% |
| 50-Day Moving Average | 528.77 |
| 200-Day Moving Average | 579.08 |
| Relative Strength Index (RSI) | 43.81 |
| Average Volume (20 Days) | 1,400,134 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaEssentia had revenue of TWD 11.34 billion and earned 3.90 billion in profits. Earnings per share was 11.67.
| Revenue | 11.34B |
| Gross Profit | 9.99B |
| Operating Income | 2.82B |
| Pretax Income | 4.12B |
| Net Income | 3.90B |
| EBITDA | 2.94B |
| EBIT | 2.82B |
| Earnings Per Share (EPS) | 11.67 |
Balance Sheet
The company has 22.03 billion in cash and 984.94 million in debt, giving a net cash position of 21.05 billion or 63.16 per share.
| Cash & Cash Equivalents | 22.03B |
| Total Debt | 984.94M |
| Net Cash | 21.05B |
| Net Cash Per Share | 63.16 |
| Equity (Book Value) | 29.12B |
| Book Value Per Share | 87.45 |
| Working Capital | 23.93B |
Cash Flow
In the last 12 months, operating cash flow was 3.91 billion and capital expenditures -945.22 million, giving a free cash flow of 2.97 billion.
| Operating Cash Flow | 3.91B |
| Capital Expenditures | -945.22M |
| Free Cash Flow | 2.97B |
| FCF Per Share | 8.90 |
Margins
Gross margin is 88.12%, with operating and profit margins of 24.90% and 34.38%.
| Gross Margin | 88.12% |
| Operating Margin | 24.90% |
| Pretax Margin | 36.34% |
| Profit Margin | 34.38% |
| EBITDA Margin | 25.91% |
| EBIT Margin | 24.90% |
| FCF Margin | 26.16% |
Dividends & Yields
This stock pays an annual dividend of 1.10, which amounts to a dividend yield of 0.22%.
| Dividend Per Share | 1.10 |
| Dividend Yield | 0.22% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.10% |
| Shareholder Yield | -0.88% |
| Earnings Yield | 2.30% |
| FCF Yield | 1.75% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PharmaEssentia has an Altman Z-Score of 31 and a Piotroski F-Score of 6.
| Altman Z-Score | 31 |
| Piotroski F-Score | 6 |